PHARMA8K'S

Amgen (AMGN) announced the retirement of Executive Vice President and Chief Financial Officer, Peter H. Griffith, effective August 31, 2026.

BeiGene announced that BEQALZI™ (sonrotoclax) received accelerated approval from the U.S. FDA on May 13, 2026. This approval is for the treatment of adult patients with relapsed or refractory mantle c...

Biogen (BIIB) announced the completion of its acquisition of Apellis Pharmaceuticals on May 14, 2026. The acquisition was finalized following a successful tender offer where Biogen acquired approximat...

Halozyme Therapeutics, Inc. filed an 8-K report on May 11, 2026, announcing its financial results for the first quarter ended March 31, 2026. The filing includes a press release (Exhibit 99.

Gilead Sciences filed an 8-K on May 7, 2026, announcing its financial results for the quarter ended March 31, 2026. The filing includes a press release (Exhibit 99.

Elanco Animal Health Incorporated filed an 8-K on May 6, 2026, reporting its financial results for the first quarter of 2026 (ended March 31, 2026).

Pfizer Inc. filed an 8-K on May 5, 2026, announcing its financial results for the first quarter of 2026. The filing includes a press release (Exhibit 99.1) detailing the company's performance.

Vertex Pharmaceuticals Incorporated filed an 8-K on May 4, 2026, announcing its financial results for the first quarter of 2026 (three months ended March 31, 2026).

BioMarin Pharmaceutical Inc. filed an 8-K on May 4, 2026, announcing its financial results for the first quarter ended March 31, 2026. The filing includes a press release (Exhibit 99.

Jazz Pharmaceuticals plc (JAZZ) filed an 8-K on May 1, 2026, reporting its financial results for the first fiscal quarter ended March 31, 2026. The filing includes a press release (Exhibit 99.